Certolizumab-methotrexate combo effective in early RA

The anti-TNF agent certolizumab pegol can be successfully used earlier in the course of RA in patients with high anti-CCP antibody levels, a clinical trial suggests.

When given as first-line therapy alongside methotrexate in these patients, certolizumab (Cimzia) slowed joint damage progression and increased remission rates compared to placebo, Japanese researchers report.

Fifty eight per cent of